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In this discussion we propose to describe the use of cyclophosphamide in 
immunosuppressive regimens that recently have been employed for humans 
after whole organ transplantation. Before doing this it might be well to 
briefly go back over some major principles of immunosuppressive therapy 
that were worked out almost a decade ago with drugs other than 
cyclophosphamide. Almost all of this basic information came from the 
accurate observation of patients subjected to the relatively simple operation 
of renal homotransplantation. 
REVERSAL OF REJECT/ON AND RELATIVE GRAFT 
« ACCEPTANCE» 
Some typical events subsequent to renal homotransplantation are 
illustrated in Figure I. This 23-year-old patient was given a renal homograft 
by his younger brother in early 1963. After transplantation, the drug 
azathioprine (ImuranR ) was given in an attempt to prevent rejection. There 
was prompt and excellent function of the new kidney with large volumes of 
urine, a spectacular rise in creatinine clearance, and a fall in BUN. 
However, after a little more than 2 post-operative weeks the new kidney 
began to fail. The creatinine clearance dropped sharply, the BUN rose 
secondarily, the urine volume diminished and the patient gained weight. In 
addition, there was an increase in the white cell count. He developed 
hypertension which required control by antihypertensive medications, 
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Fig. l. - Classical rejection crisis III a patient being treated with the double-
drug combination of azathioprine (lmuran) and prednisone. Deterioration of re-
nal function b~gan 17 days after transplantation. All stigmata of rejection were 
present except for acute hypertension and weight gain, which were successfully 
prevented by medical treatment. The patient, whose transplantation was on April 
17, 1963, still has excellent function of the same homograft 9 years later. Biopsy 
of the homograft after two years was normal. Acti-C - actinomycin C; LN -
left nephrectomy at the time of transplantation; RN - right nephrectomy. (By 
permission of Surg. Gynec. Obstet. 1 J 7: 385, 1963). 
became acutely febrile with temperatures of almost 40 'C, and developed 
proteinuria. In short, all the manifestations of acute rejection had developed 
in spite of immunosuppressive therapy, namely signs of acute homograft 
failure plus an acute systemic febrile illness. 
Before experience with this patient and others of the same era in the early 
1960's, it had been assumed that rejection was one of biology's most 
vigorous and persevering reactions and that, once begun, it would continue 
to the death of the transplant. It was now proved that this assumption was 
false and that rejection was a highly reversible process. In this case, 
immunosuppressive treatment was intensified by the addition of prednisone 
to the azathioprine. The findings of rejection promptly disappeared. The 
BUN fell, the creatinine clearance rose, and the proteinuria disappeared as 
did the high blood pressure. The fever was gone within a few hours of the 
institution of the prednisone therapy. Rejection had thus been shown to be a 
reversible process. This was a fundamental disclosure by clinicians and one 
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which had not been at all anticipated by previous workers in basic research 
laboratories. 
The second equally important thing learned from these early patients can 
also be demonstrated by the same case. In the weeks after rejection had 
been reversed in this patient, the prednisone dose was very rapidly reduced, 
and eventually it was discontinued altogether after only about 5 months. 
Then the azathioprine dose was also lowered until within a year the patient 
was receiving only about half the daily quantities that at the outset had 
failed to prevent the onset of a moderately severe rejection. It is quite 
possible that all immunosuppressive therapy could be stopped in this patient 
who is still alive with perfect renal function after almost 9 years. Although 
we have ·never felt justified in taking the final drastic step of stopping 
treatment in any human recipient, we have thoroughly tested the hypothesis 
in dogs. We have animals in our laboratory surviving for as long as 9 years 
and 8 years, respectively, after renal and hepatic homotransplantation from 
non-related mongrel donors. These remarkable dogs who, it is now clear, are 
apt to die of old age, were treated with azathioprine for only a few months 
post-operatively and have not now received any treatment for approximately 
2 / 3 of a canine lifetime. 
Even in this introduction it is worth summarizing the two concepts which 
have just been stated. First, rejection is a highly reversible process. Second, 
a favorable change often occurs after transplantation by virtue of which the 
host comes to better tolerate the presence of the homograft, thereby allowing 
immunosuppression to be reduced. If either of these statements were not 
true, organ transplantation would not be feasible. The fact that they are true 
is the inside story of clinical transplantation. The observations supporting 
these two conclusions indicate that whole organ homotransplantation in 
conjunction with non-specific immunosuppressive therapy can and often 
does lead to selective abrogation of the host rejection response. From a 
practical point of view, this objective is most easily achieved by the use of 
pharmacologie agents in combination. In fact, the modem era of clinical 
transplantation was ushered in by the realization (illustrated in Figure 1) 
that azathioprine and prednisone can advantageously be used together with 
an effect exceeding the simple sum of the individual drugs. This 
combination of agents has been referr-ed to as the « double drug regimen. » 
THE TRIPLE DRUG REGIMEN OF AZATHIOPRINE, 
PREDNISONE, AND ALG 
A third potent immunosuppressive agent that has been widely employed 
is heterologous antilymphocyte globulin (ALG). When given subcutaneously, 
intramuscularly, or intravenously, it has been shown as the sole treatment to 
mitigate or prevent rejection. Moreover, it has an additive effect when 
administered with either azathioprine or prednisone. 
In our clinics, ALG has been administered as a third agent, added to 
azathioprine and prednisone, in almost all organ recipients treated from 
May, 1966 to the end of 1970. In most cases the course of ALG therapy 
was limited to the first 4 post-operative months, during that critical time 
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Fig. 2. - The course of a patient who received antilymphocyte globulin (ALG) 
before and for the first four months after renal homotransplantation. The donor 
was an older brother. There was no early rejection. Prednisone therapy was star-
ted 40 days postoperatively because of the high rises in the serologic titers which 
indicated a host response against the injected foreign protein and which warned 
against a possible anaphylactic reaction: Note the insidious onset of late rejection 
after cessation of globulin therapy. Tliis was treated by increasing the mainte-
nance dose of steroids. (By permission of Surg. Gynec. Obstet. 126: 1023, 1968). 
when « graft acceptance» is hoped for (Figure 2). We have referred to this 
treatment program as a triple drug regimen as opposed to a double drug 
regimen consisting of azathioprine and prednisone only that was used before 
1966. . 
With the institution of the foregoing triple drug program there has been 
an improvement in the results after renal transplantation at our center. 
Other workers including those in Lyon, Minneapolis, Salt Lake City, Sydney 
and Boston have shared this same opinion of the benefits of adding ALG, 
although it must be conceded that acceptance of ALG as an important 
comF'onent of treatment has not yet been universal.' This question is an 
interesting and unresolved one but we will not be able to dwell on it since it 
is outside the main focus of the present communication. 
CYCLOPHOSPHAMIDE 
With both the double drug and triple drug programs just described, 
azathioprine has been considered the cornerstone agent. As such, 
azathioprine has acquired the mystique that goes with presumed 
indispensibility. The present report will show that another well-known 
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cytotoxic drug, namely cyclophosphamide (or Cytoxan) is approximately as 
potent and safe as azathioprine. At the least, it can be administered 
interchangeably with azathioprine, but hopefully its use may lead to 
something more than just the advantage of having a major « back-up» drug. 
As many of you know; azathioprine is a purine analogue. Its site of action 
has been described by Elion and Hitchings to be principally at the DNA 
synthesis (or S) phase of the cell cycle (Figure 3). The presumption is that 
AZA'fHlIOlPRlINlE CYClLOlPHO§lPHAMlIDlE 
~ "S" ~ 
"G I " 
(Interphase) 
Fig. 3. - Sites of action during the cell cycle of the cytotoxic drugs, 
azathioprine and cyclophosphamide. Rapidly replicating lymphoid cells are pre-
sumably preferentially susceptible to destruction by either agent. 
the metabolically active lymphoid tissue which subserves cell-mediated re-
jection is thus injured and thereby prevented from m.ounting an effective 
rejection. In contrast, cyclophosphamide is classified as an alkylating agent, 
chemically similar to nitrogen mustard. Its site of action, according to Wheeler, 
is at the G2 (or resting)phase of the ccll cycle, just preceding mitosis (Figure 3). 
Cyclophosphamide in the Triple Drug Regimen 
Patient and Kidney Mortality - Although cyclophosphamide is 
fundamentally different from azathioprine it has proved capable of 
performing precisely the same role as exemplified in Figure 4. The patient 
whose early course is depicted received a kidney more than seven months 
ago from a mismatched cadaveric donor. Cyclophosphamide was given 
instead of azathioprine but in doses that were less than half of what would 
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Fig. 4. - The uncomplicated early convalescence of a cadaveric renal homograft 
recipient treated with cyclophosphamide, prednisone, and ALG. This patient did 
not experience a rejection episode. (By permission of Lancet 2 : 70, 1971). 
have been anticipated with azathioprine. Rejection in this case was never 
diagnosed despite the rapid withdrawal of prednisone therapy. ALG was 
also given initially and later stopped. 
Figure 5 illustrates the course of another recipient, this time of a maternal 
kidney. A week after operation there was a severe rejection crisis of the 
kind first observed under azathioprine therapy almost a decade ago. The 
findings included recurrent azotemia, a fall in creatinine clearance, oliguria, 
proteinuria, and hypertension. The crisis was controlled and reversed by 
temporarily increasing the prednisone dosage. The patient was never given 
enough cyclophosphamide to depress her white count. This we believe to be 
the secret of successful cyclophosphamide therapy. In this case, the eventual 
daily doses were 25 mg or less, or smaller than a half a milligram per 
kilogram per day. 
Six to 11 months ago (February to July, 1971) we treated 18 consecutive 
intrafamilial kidney recipients with the cyclophospha!Uide-containing triple 
drug regimen. Two of the kidneys underwent hyperacute rejection and were 
removed immediately or within a few hours; these patients subsequently 
died after retransplantation. Two other recipients died of perforated 
diverticulitis and pneumonitis, respectively, for a total patient mortality of 
22 %. The other 14 homografts are all functioning satisfactorily (Table 1). 
In the 3 months from December, 1970 to March, 1971, a comparable 
group of 20 intrafamilial recipients were treated with the standard triple 
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Fig. 5. - The first 60 days after the transplantation of a kidney from a mother 
to her daughter. Allthough the rejection crisis after a week was a severe one, it 
was easily and completely reversed. Note that leukopenia was never produced by 
the daily doses of cyclophosphamide that were usually between 0.5 to 1.0 mg per 
kg/ day. ALG - horse antilymphocyte globulin; BUN - blood urea nitrogen; 
CCr - creatinine clearance; WBC - white blood cell count; ARROW - 625 
mg methyl prednisolone intravenously. (By permission of Surg. Gynec. Obstet. 
133: 981, 1971). 
Tahie I. - Intrafamilial transplantation. 
18 Cyclophosphamide 20 Azathioprine 
Functioning Grafts* 14 (78 %) 16 (80 %) 
Hyperacute Rejection 2 (11 %)** 1 (5 %) 
Patient Dead* 4 (22 %) 3 (15 %) 
* Follow-ups in the cyclophosphamide cases are 6 to 1 r months; the follow-ups 
in the azathioprine cases are 11 to 15 months. 
** Both these patients died. 
drug program containing azathioprine. The results were essentially the same 
(Table 1). 
In addition to these intrafamilial cases, 17 cadaveric renal 
transplantations were also performed under cyclophosphamide. 
Comparisons with azathioprine were difficult here since the cases were more 
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complicated and included numerous retransplantations. In fact, 46 % of the 
recipients (12 of 26) were undergoing retransplantation for the second to the 
fifth time. In the cyclophosphamide group the kidney survival to date has 
been about two-thirds, somewhat better than in the azathioprine controls 
(Table 2). 
Tahle 2. - Cadaveric transplantation* 
17 Cyclophosphamide** 9 A zathioprine** 
Functioning Grafts 11 (65 %) 5 (56 %) 
Hyperacute Rejection 1 1 
Graft Rejected 2 2 
Patient Dead 3 (18 %) 2 (22 %) 
* 12 of these 26 recipients were undergoing retransplantation from the second to the 
fifth times, helping to explain the relatively poor results in both groups. 
** Follow-ups in the cyclophosphamide cases are 6 to 11 months; the follow-ups 
in the azathioprine cases are 11 to 15 months. 
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Fig. 6. - Incidence of toxicity in the first 2 months of treatment of renal homo-
graft recipients with cyclophosphamide versus azathioprine. At the'· doses used, 
tbere was little obvious difference between the 2 agents. The one patient under 
cyclophosphamide therapy who developed major hepatic dysfunction had a pro-
ven attack of acute serum hepatitis, Australia antigen positive. (By permission of 
Surg. Gynec. Obstet. 133: 981, 1971). 
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Relative Toxicity - As with so many other really important things in 
organ transplantation, Dr. Will Goodwin of Los Angeles pioneered the use 
of cydophosphamide almost a decade ago. Unfortunately, in these early 
days of its use in transplantation and for cancer chemotherapy, 
cyclophosphamide acquired the reputation of being terribly toxic. We now 
believe that this bad name was the product of overdosage. In the doses used 
for our patients, the incidence of serious infections and bone marrow 
depression were not different than in control cases using azathioprine as 
shown in Figure 6. The relatively specific complications of 
cyclophosphamide, such as gastrointestinal complaints, alopecia and 
hemorrhagic cystitis were either not common or were not observed at all. 
To give some idea of relatively safe doses of cyclophosphamide in relation 
to those of azathioprine, the statistical study depicted in Figure 7 was 
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Fig. 7. - Drug doses and laboratory measurements at the end of one and two 
months in patients given either cyclophosphamide or azathioprine. All these re-
cipients of kidneys donated by blood relatives were also treated with prednisone 
and horse- antilymphocyte globulin. The p value are noted only for differences 
that were statistically significant. (By permission of Surg. Gynec. Obstet. /33: 
981, 1971). 
carried out in the patients described in the preceding section who received 
consanguineous kidneys and who lived for at least two postoperative 
months. The doses of cyclophosphamide per body weight were about 40 % of 
those with azathioprine. With these 2 different cytotoxic drugs the creatinine 
clearances, the BUN, the daily quantities of prednisone, and the average 
white cell counts were not significantly different. 
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Cyclophosphamide Substitution 
From the foregoing observations, it seemed that cyclophosphamide and 
azathioprine played a very similar role as the cytotoxic agent in triple drug 
therapy. This conclusion was supported from the study of an additional 49 
patients in whom pre-existing therapy with azathioprine was stopped from 6 
weeks to 8 years after renal transplantation and replaced with 
cyclophosphamide as in the recipient of a cadaveric kidney graft whose 
course is shown in Figure 8. After the change in this patient, renal function 
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Fig. 8. - The consecutive use of azathioprine and cyclophosphamide after cada-
veric renal homotransplantation. The change to cyclophosphamide was made be-
cause of dissatisfaction with the early postoperative course. There was slow im-
provement in the subsequent convalescence but, retrospectively. there is no 
reason to believe that this might not have occurred even without making the 
drug switch. ALG - horse antilymphocyte globulin. The globulin injections 
were daily for 10 days, every other day for 20 days, and twice a week until they 
were discontinued because of anaphylactic reactions. BUN - blood urea nitro-
gen ; CCr - creatinine clearance; WBC - white blood cell count. (By permis-
sion of Surg. Gynec. Obstet. 133 : 981, 1971). 
was maintained and, in fact, it became possible to reduce the doses of 
prednisone. With almost no exceptions, the preexisting condition of the 49 
patients was not altered by the drug change. 
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Specific Present Indications 
For Cyclophosphamide Substitution 
For the moment, we would like from this experience to leave with you 
one small but practical point. There will be specific indications for 
cyclophosphamide as exemplified by a patient (Figure 9) who was dying of 
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Fig. 9. -- The course of a patient in whom azathioprine was stopped becaase of 
the suspicion of hepatotoxicity. Multiple Australia antigen tests for sennn he-
patitis were negative. Note the recession of jaundice after the substitution of cy-
clophosphamide for azathioprine. BUN-- blood urea nitrogen; SGOT -- serum 
glutamic oxaloacetic transaminase in international UJ;lits; WBC -- white blood 
cell count. (By permission of Surg. Gynec. Obstet. 133 : 981, 1971). . 
liver disease after an otherwise successful renal transplantation. The hepatic 
injury was suspected to be due to azathioprine for which 'reason this agent 
was stopped and replaced with cyclophosphamide almost one year ago. The 
renal function was perfectly maintained and eventually there was complete 
recovery from the liver injury. We have encountered other examples of relief 
of hepatoxicity after making the drug switch. 
Future Prospects 
It is of considerable theoretic~l interest that azathioprine and 
cyclophosphamide can be used essentially interchangeably since they are of 
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different drug classes and are thought to have different actions. But does 
this fact imply that sweeping improvements in clinical immunosuppression 
will be made possible simply by the wider routine use of 
cyclophosphamide? If so, we believe that cyclophosphamide and 
azathioprine will have to be used by techniques of sequential rather than 
cotemporaneous administration. Since last summer, we have treated about 
35 kidney recipients with this principle, which is an extremely simple one.-
For the first three to eight post-operative weeks the triple drug treatment is 
given with cyclophosphamide, prednisone, and horse ALG. The doses of 
cyclophosphamide are kept at or above lmg/kg/day. As soon as these doses 
cause significant drops in' the white count, or arbitrarily at the end of 8 
weeks, the cyclophosphamide is stopped and replaced with azathioprine for 
chronic maintenance therapy (Figure 10). 
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Fig. 10. - The first 2 post-transplantation months of a 14 year old recipient of a 
paternal homograft. Her initial immunosuppressive therapy was with cyclophos-
phamide, prednisone and horse antilymphocyte globulin (ALG). The daily doses' 
of cyclophosphamide were always greater than 1.3. mg/ kg/ day and were given 
for the first 33 days post-operatively. The switch to azathioprine was then 
made because of a progressive decline in the white blood cell count. The re-
cipient has never had a rejection episode and her renal function continues to be 
normal 3 months post-transplantation. 
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It is too early to judge the efficacy of this most recently evolved 
therapeutic protocol but at the moment the results .are encouraging. Only 
one patient has died. One additional kidney has been lost, but this was the 
consequence of a technical error. While we do not know if this therapeutic 
program is superior to the standard triple drug program used in the past, 
were are quite certain it is at least as good. 
Summary 
In one regimen or other, cyclophosphamide has been given to almost all 
renal homograft recipients treated in Denver in the last year, to a total of 
nearly 100. In addition, cyclophosphamide was substituted for azathioprine 
in 49 more recipients at varying times post-transplantation. The 
immunosuppressive potency and the safety of cyclophosphamide have been 
equivalent to that of azathioprine, indicating that there are now two first-
line and apparently interchangeable agents for use in whole organ 
transplantation. The present practice is to use cyclophosphamide for all 
fresh cases for 3 weeks to 2 months and then to switch to azathioprine for 
chronic therapy. Since cyclophosphamide and azathioprine have different 
actions on their target cells, it is hoped that the transition from one to the 
other agent might promote a more effective kill of immunologically 
competent cells which are replicating in response to the antigenic stimulus. 
Whether or not this is true will have to be determined by further clinical 
observations and controlled laboratory experiments. 
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